BIOCRYST PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.53 million shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2023-02-27
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2013-12-31 was 177.00K shares, a 68.95% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2013-09-30 was 536.00K shares, a 750.79% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2013-06-30 was 253.00K shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2013-03-31 was 835.00K shares.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.53M shares, a 277.15% increase from fiscal 2021.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 407.00K shares, a 74.50% decline from fiscal 2020.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 1.60M shares, a 126.70% increase from fiscal 2019.
- BIOCRYST PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 704.00K shares, a 517.54% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2022-12-31 | 1.53M shares 10-K · filed 2023-02-27 | |||
| 2021-12-31 | 407.00K shares 10-K · filed 2022-02-28 | |||
| 2020-12-31 | 1.60M shares 10-K · filed 2021-03-01 | |||
| 2019-12-31 | 704.00K shares 10-K · filed 2020-03-13 | |||
| 2018-12-31 | 114.00K shares 10-K · filed 2019-03-14 | |||
| 2017-12-31 | 395.00K shares 10-K · filed 2018-03-12 | |||
| 2016-12-31 | 235.00K shares 10-K · filed 2017-02-27 | |||
| 2015-12-31 | 28.00K shares 10-K · filed 2016-02-26 | |||
| 2013-12-31 | 177.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | 713.00K shares derived: sum of 2 quarters · filed 2014-03-10 | 966.00K shares derived: sum of 3 quarters · filed 2014-03-10 | 1.80M shares 10-K · filed 2014-03-10 |
| 2013-09-30 | 536.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | 789.00K shares derived: sum of 2 quarters · filed 2013-11-08 | 1.62M shares 10-Q · filed 2013-11-08 | 2.19M shares derived: sum of 4 quarters · filed 2014-03-10 |
| 2013-06-30 | 253.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | 1.09M shares 10-Q · filed 2013-08-08 | 1.66M shares derived: sum of 3 quarters · filed 2014-03-10 | 1.72M shares derived: sum of 4 quarters · filed 2014-03-10 |
| 2013-03-31 | 835.00K shares 10-Q · filed 2013-05-09 | 1.41M shares derived: sum of 2 quarters · filed 2014-03-10 | 1.47M shares derived: sum of 3 quarters · filed 2014-03-10 | |
| 2012-12-31 | 570.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | 633.00K shares derived: sum of 2 quarters · filed 2014-03-10 | 1.05M shares 10-K · filed 2014-03-10 | |
| 2012-09-30 | 63.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | 482.00K shares 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | 419.00K shares 10-Q · filed 2012-08-08 | |||
| 2011-12-31 | 584.00K shares 10-K · filed 2014-03-10 | |||
| 2010-12-31 | 335.00K shares 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |